{"id":"NCT00445432","sponsor":"Abbott","briefTitle":"A Study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects With Crohn's Disease","officialTitle":"A Multi-Center, Randomized, Double-blind, Placebo-controlled Study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects With Crohn's Disease","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2007-03","primaryCompletion":"2009-03","completion":"2010-11","firstPosted":"2007-03-09","resultsPosted":"2010-06-09","lastUpdate":"2012-02-02"},"enrollment":82,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Crohn's Disease"],"interventions":[{"type":"BIOLOGICAL","name":"adalimumab","otherNames":["Humira","D2E7"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"DB Adalimumab 40 mg eow","type":"EXPERIMENTAL"},{"label":"Placebo eow","type":"PLACEBO_COMPARATOR"},{"label":"OL Adalimumab 40 mg eow","type":"EXPERIMENTAL"}],"summary":"To demonstrate the efficacy and safety of adalimumab for the maintenance of clinical remission in Japanese subjects with Crohn's disease.","primaryOutcome":{"measure":"Number of Participants Who Had Clinical Remission at Week 52 of Double-blind Treatment","timeFrame":"Week 52 of double-blind treatment","effectByArm":[{"arm":"DB Adalimumab 40 mg Eow","deltaMin":8,"sd":null},{"arm":"Placebo Eow","deltaMin":2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"15 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":29,"countries":["Japan"]},"refs":{"pmids":["24874893","22325170"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":25},"commonTop":["Nasopharyngitis","Adverse drug reaction","Crohn's disease","Dental caries","Pyrexia"]}}